1. Evaluation of autoantibodies as predictors of treatment response and immune‐related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan‐cancer study. (16th March 2022) Authors: Barth, Dominik A.; Stanzer, Stefanie; Spiegelberg, Jasmin; Bauernhofer, Thomas; Absenger, Gudrun; Posch, Florian; Lipp, Rainer; Halm, Michael; Szkandera, Joanna; Balic, Marija; Gerger, Armin; Smolle, Maria A.; Hutterer, Georg C.; Klec, Christiane; Jost, Philipp J.; Kargl, Julia; Stradner, Martin;... Journal: Cancer medicine Issue: Volume 11:Number 16(2022) Page Start: 3074 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up. (November 2022) Authors: Fluhrer, Hannah; Hutterer, Georg C.; Golbeck, Sylvia; Stidl, Michael; Niedrist, Tobias; Pichler, Renate; Mischinger, Johannes; Seles, Maximilian; Mannweiler, Sebastian; Spiegelberg, Jasmin; Bauernhofer, Thomas; Jost, Philipp J.; Ahyai, Sascha; Zigeuner, Richard; Pichler, Martin; Barth, Dominik A. Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗